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Background: The Japanese Government settled a class litigation case with hepatitis B virus (HBV) carriers who
claim to have been infected through needle/syringe sharing in childhood mass vaccination with a blanket
compensation agreement. However, it is difficult to estimate how many of the present HBV carriers were infected
horizontally from mass vaccination and how many were infected vertically from mothers.
Methods: A mathematical model to predict the risk of infection through needle/syringe sharing in mass
vaccination was proposed and a formula was developed. The formula was presented in a logarithmic graph
enabling users to estimate how many people will be infected if a needle/syringe is shared by how many people for
how many times under certain probability of infection. The formula was then applied to the historical data of mass
tuberculin skin tests (TSTs) and BCG inoculation, from which a best estimate of how much needle/syringe sharing
was practiced in different birth cohorts was determined.
Results: For the oldest cohort born between 1951 and 1955, the prevalence of HBV carriers—0.65% at birth
through vertical transmission—more than doubled in 1995 (1.46%) through horizontal transmission. If the
probability of infection through needle/syringe sharing is assumed to be 10%, it is theoretically likely that an
average of five or more people shared a needle/syringe four times to achieve the prevalence of HBV carriers in
1995. However, for the youngest cohort born between 1981 and 1985, the effects of needle/syringe sharing were
negligible because the later prevalence of HBV carriers was lower than the prevalence at birth.
Conclusions: More than half of the HBV carriers born in the early 1950s might have contracted the disease by mass
vaccinations. Japan’s experience needs to be shared with other countries as a caution in conducting mass
vaccination programs under scarce needle/syringe supply (291 words).
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Nations.Background
Historically, Japan, as well as most Asian countries, has
a high prevalence of hepatitis B and C virus (HBV,
HCV) carriers [1]. In 1989, five HBV carriers sued the
Government claiming that they had been infected withCorrespondence: atoz@niph.go.jp
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reproduction in any medium, provided the orthe virus through needle/syringe sharing in childhood
mass vaccination [2]. In 2002, another group of HCV car-
riers also filed a class litigation case against the Govern-
ment and pharmaceutical manufacturers claiming that
they had been infected iatrogenically through tainted
blood products (fibrinogen) [3].
In 2008, the Government accepted an out-of-court
settlement with the HCV plaintiffs setting the precedents
of damages (e.g., 36 million yen [approximately $US
370,000] for deaths, liver cancer, and cirrhosis caused by
HCV) [4]. The Government accepted another settlement
with the HBV plaintiffs in June 2011 with a blanket com-
pensation agreement: Awarding the same damages to all. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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syringe sharing in childhood mass vaccination [5].
The potential financial burden of the blanket compen-
sation could be gigantic given the high prevalence of
HBV among the Japanese population, and the unknown
prospect of how many were infected from needle/syringe
sharing in mass vaccination and how many were not.
Since almost the entire Japanese population was vacci-
nated in childhood before 1988, when syringe sharing
was officially banned (needle sharing was banned for
tuberculin skin test (TST) in 1950 [6] and for mass vac-
cination in 1958 [7]), the total amount of damages could
reach up to 3.2 trillion yen ($US 32 billion, estimates by
Ministry of Health, Labour and Welfare) if all HBV car-
riers are entitled to compensation.
The settlement with the HBV plaintiffs included a
mandate that the Government investigate the extent of
needle/syringe sharing at that time, and the reason why
such risky practice was left uncontrolled. A research
group was organized to conduct questionnaire surveys
with municipal governments and interviewed retired
public health officers about how mass vaccinations were
conducted at that time. The findings were compiled as a
400-page report [8]. Unfortunately, the results—not sur-
prisingly—were disappointing. The research group sent
questionnaire to 1,701 municipal governments and re-
ceived 1,149 replies (67.5%), of which only 11 replied
that they kept records of mass vaccinations from 1962
or before, and only four for 1954 or before (the rest
replied that they had no records from those times). The
research group also sent questionnaire to 61 retired di-
rectors of public health centers and only 37 responded
(60.7%). Of the 33 who responded to the question on
whether they instructed needle/syringe exchange, 17 did
not reply or replied that they had no memory. Eleven
replied that they had instructed that the needle/syringe
must be exchanged individually, however five of them
replied that they had not. One of the respondents apolo-
gized by writing “I am now 86 and suffering from a
stroke. I cannot answer correctly about experiences that
happened such a long time ago…”.
Hence, there is a need to develop a statistically sound
model and a formula to predict how many of the current
HBV carriers are considered to have been infected
through needle/syringe sharing in mass vaccination.
Since it is difficult to demonstrate with evidence how
needle/syringe sharing was practiced such a long time




Ethical approval was not sought because this study is a
theoretical one using administrative data only.A mathematical model
The chance of having i infected persons in a group of n
with a prevalence of p sharing a needle/syringe follows a
binomial distribution: B(i;n,p). When there are i infected
persons in a group of n, the number of uninfected per-
sons is n-i.
The chances of an uninfected person receiving a shot
BEFORE i infected persons (i.e., the chance of the unin-
fected person escaping the infection) is expressed as
1/(i + 1) because there are a total of (i + 1) persons in-
cluding both the uninfected person and the i infected
persons who have equal chances of receiving a shot
ahead of others. Then, the chance of an uninfected per-
son getting infected for receiving a shot AFTER any of
infected persons is i/(i + 1).
New infections will not occur where none or all of the
n persons sharing a needle/syringe are infected. New
infections only occur when there is one or more (1 < =
i < =n-1) infected persons in a group of n sharing a
needle/syringe. Hence, the expected number of people in
a group of n being infected is the sum of B(i;n,p)*(n-i)*i/
(i + 1) for 1 < =i < =n-1. Note that the chance of getting in-
fected depends on the number of infected persons, i, in
the group and is NOT related to the size of the group
sharing a needle/syringe, n. The logic is illustrated in
Figure 1.
Let’s assume that an uninfected person gets infected
from an infected person when a needle/syringe is shared
by n people in a mass vaccination, and the uninfected
person receives a shot AFTER the infected person with
the probability r. When such a mass vaccination is con-
ducted in a population with a prevalence of the disease
p, the number of newly infected persons K is expressed
as follows:
K ¼ r  ∑n−1i¼1 B i; n; pð Þ 




Hence, the prevalence after a mass vaccination will be
increased by K/n resulting in the new prevalence of
p + K/n.
Graphical presentation
The formula (1) is presented graphically with changing pa-
rameters: n and p where r is set at 1 (see Figure 2). The
risk of a new infection increases as the prevalence and the
number of people sharing a needle/syringe increases. In a
population with prevalence of 1% of a disease, 2% of the
population will be newly infected if a needle/syringe is
shared by five people, resulting in 3% prevalence after a
mass vaccination. If a needle/syringe is shared by 20
people, it will newly infect 9% of the population making
the resultant prevalence of 10%. If the prevalence is 10%
and a needle/syringe is shared by 80 people, it will infect
Figure 1 Illustration of a formula to predict the number of new infection.
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left uninfected. However, once the prevalence of a disease
exceeds a certain level, the number of new infections will
be less because there will be fewer uninfected persons.Application of the mass TST and BCG inoculation
program
The mass tuberculin skin test (TST) program was en-
forced pursuant to the Tuberculosis Control Act and
almost every newborn baby received a TST. The formula
(1) was applied to estimate the number of HBV carriers
infected through needle/syringe sharing in mass TST
with the following assumptions.Figure 2 Graphical presentation of the formula to predict new infectiMass TST and BCG inoculation program
Control of tuberculosis (TB) was one of the most im-
portant public health issues in Japan, and mass TST and
BCG inoculations on those with negative results have
been conducted pursuant to the Tuberculosis Control
Act. The data on age-specific (0–5 year olds) number of
TST and BCG recipients were taken from the annual
reports of public health centers from 1951 onwards (see
Figure 3). The administrative reports summarized public
health center activities, and data definition and collec-
tion procedures were consistent over the years. However,
age groups were not so consistent. The data between
1960 and 1965 are aggregated in all ages, and children’s
data were not available and hence excluded fromon rate through needle/syringe sharing.
Figure 3 Prevalence of HBV carriers and mass tuberculin skin tests/BCG inoculation of children born 1951-85.
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pertussis, and typhoid fever were also responsible for
HBV infection but they were not included in the analysis
because age-specific data were not available over the
years.
Since needle/syringe sharing was officially banned in
January 1988 and the prevention program for HB mother-
to-infant transmission was fully introduced in 1986, birth
cohorts born between 1951 and 1985 were focused on.
Children with negative (plus quasi-negative) TST re-
ceived BCG inoculations. On average, children born bet-
ween 1951 and 1959 received two or more injections.
The reports before 1959 do not provide the number of
people injected. In 1967, BCG was changed to adisposable stamping method and the risk of iatrogenic
infection through BCG was eliminated in children born
in this year or later. Still, children born between 1966
and 1985 received, on average, one or more TST.
Prevalence of HBV carriers among mothers and pre-school
children
Prevalence of HBV carriers (HBsAg(+)) among mothers
and pre-school children are not known before a certain
time and must be estimated. Since almost all HBV car-
riers are attributable to vertical (mother-to-infant) trans-
mission and the risk is highest when mothers are HBeAg
(+), in which case 85–90% of newborn babies will be
HBV carriers [9], the prevalence of HBV carriers among
Okamoto Infectious Diseases of poverty 2013, 2:28 Page 5 of 9
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of mothers can also be estimated.
Mori reported the prevalence of HBsAg(+) among preg-
nant mothers examined at Yokohama city public health
centers (N = 18,152 or approximately 11% of pregnant
mothers in the city) between 1976 and 1980 as 2.0% (358/
18152) [10].
As well as that, the prevention program to eliminate
mother-to-infant transmission of hepatitis B, introduced
in 1986, provides a national estimate of the prevalence
of HBV carriers among pregnant mothers and newborn
babies [11]. Shiraki estimated the prevalence of HBV car-
riers among newborn babies born in 1985 as 0.26% by
multiplying the prevalence of HBV carriers among preg-
nant mothers (1.36%) with the rate of HBeAg(+) (22.5%)
and the probability of a newborn baby to become a
carrier (85%) [12]. Theoretically, the prevalence of HBV
carriers infected vertically through mother-to-infant
transmission will be reduced to 20% (0.225*0.85 = 0.2) in
every generation without any preventive measures. If the
prevalence in later generations is higher than expected,
it suggests augmentation through horizontal transmis-
sion such as mass vaccinations or other routes of
infection.Figure 4 Prevalence of HBsAg (+) among pregnant mothers.The author applied a trend line to all available data
and obtained the following regression formula with high
R2 (0.962) (see Figure 4). The prevalence of HBV carriers
among pregnant mothers, W, in the Vth year between
1951 and 1985 can be estimated by:
W ¼ −0:0006  V þ 0:0357
This means that the prevalence of HBV carriers in
1951 was estimated to be 3.51% and decreases by 0.06%
every year. The estimated prevalence among pregnant
mothers in each year was converted into the prevalence
among newborn babies by applying Shiraki’s formula.
Based on these assumptions, the children born in 1951
were estimated to have the prevalence of HBV of 0.67%,
or roughly one out of 150 was an HBV carrier.
Current cohort-specific prevalence of HBV carriers
Children who became HBV carriers may infect other chil-
dren through mass TST and BCG inoculations, or other
mass vaccinations such as smallpox, diphtheria, typhoid,
paratyphoid, and pertussis, as well as by other means.
Children infected in their pre-school age (0–5 years old)
carry a high risk of becoming HBV carriers (the genotype
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B or C, which do not cause asymptomatic carriers unless
children under the age of six are infected. On the other
hand, genotype A causes asymptomatic carriers even
in adulthood. HBV carriers with genotype A(Ae) do not
qualify for compensation because HBV of genotype A was
not detected before 1996, and hence are not considered to
have been infected through mass vaccination before 1988
[13]). Then, the prevalence of HBV carriers in later age
should be higher than their prevalence after birth.
The author compiled three different sources estimating
age-specific prevalence of HBV carriers in 1995, 2000, and
2005 [14-16]. The first two sources provide data of ten-
year age groups and the last provides five-year age groups.
These data are presented in Figure 3 in the order of birth
cohorts.
The prevalence in 1995 was higher than the prevalence
after birth in all cohorts. The discrepancy is wider in the
older cohorts. For example, the cohort born between
1951 and 1955 was estimated to have the prevalence of
0.65% at birth. However, their prevalence in 1995 was
1.46% and then declined to 1.28% in 2005. The more
than two-fold increase between birth and middle age is
attributable to horizontal transmission either through
mass vaccination or other routes. The subsequent de-
cline of prevalence of HBV carriers in some cohorts be-
tween 1995 and 2005 could be explained by not only
hepatitis-related deaths, but also successful viral eradica-
tion thanks to improved treatment such as interferon.
Application of the mathematical model
To apply the mathematical model expressed in the for-
mula (1), one must postulate the probability of infection
of HBV, r. For this, the evidence from occupational ex-
posure provides reference.
In case of accidental needle-stick injuries, the risk of de-
veloping serologic evidence of HBV infection was 37–62%
if the needle is contaminated with blood that is both
HBsAg and HBeAg positive (the risk is lower if the HBeAg
is negative: 23–37%). On the other hand, the average inci-
dence of anti-HCV seroconversion after accidental percu-
taneous exposure from an HCV-positive source is 1.8%
(range:0–7%) and the average risk of HIV transmission
after a percutaneous exposure to HIV-infected blood is
0.3% (95% C.I.: 0.2–0.5%) [17]. Obviously, the risk of HBV
is far greater than HCV and HIV.
Accidental needle-stick injury includes hollow needle in-
jury and injury during surgery involving massive blood ex-
posure posing a high risk of transmission. On the other
hand, BCG is injected subcutaneously or intracutaneously,
and the amount of blood exposure by needle/syringe shar-
ing is considered to be smaller than those of accidental
needle-stick injuries. In view of this evidence, it would be
safe to assume that the risk of needle/syringe sharingposes a greater risk than HCV and HIV, but lower than
accidental needle-stick injuries. So, the author assumed
the probability to be 10%, somewhere between the lower
margin of accidental needle-stick injuries (23%), and the
average risk of HCV and HIV (1.8% and 0.3%).
Results
Results are summarized in Figure 3.
In case of the oldest cohort (born between 1951 and
1955), with a median prevalence of 0.65% at birth, the
prevalence of HBV carriers after repeated sharing of
needle/syringe with the probability of infection 0.1 is
illustrated in Figure 5. The average prevalence of this co-
hort in 1995 was 1.46%, and one can estimate how much
needle/syringe sharing prevalence this cohort had
“achieved” by locating a crossing of a horizontal gra-
duation (somewhere between 1% and 2%), and curves of
different average number of persons sharing a needle/
syringe. For this particular cohort to achieve 1.46% pre-
valence, they are estimated to have either 1) shared a
needle/syringe with more than 20 children one time, 2)
more than 10 children two times, 3) more than seven
children three times, or 4) more than five children four
times.
Children of this cohort received TST and BCG inocula-
tion two times on average ((C + D)/A in Figure 3). Con-
sidering other vaccinations, children in those days were
likely to receive four vaccinations, and then the above esti-
mation would tell that sharing a needle/syringe with as
few as five persons would have resulted in the increased
prevalence when they became middle aged.
In case of the youngest cohort (born between 1981
and 1985), with a median prevalence of 0.3% at birth,
sharing the needle/syringe must have been negligible be-
cause their later prevalence declined: 0.23% in 2000 and
0.15% in 2005 (their 1995 data are not available because
they were too young to donate blood at that time). This
finding suggests that although the official ban of syringe
sharing was 1988, sharing of needle/syringe was really
abandoned at the beginning of the 1980s.
Discussion
Large-scale settlements on HBV infection through mass
vaccination give a false impression that all HBV infec-
tions were caused by needle/syringe sharing in mass vac-
cination. In fact, the mass-vaccination program simply
augmented the prevalence of HBV carriers among chil-
dren. Unless an accurate estimate of how many of HBV
carriers were infected by mass vaccination is determined,
it may lead to a denial of the mass-vaccination program
and, more importantly, the contribution of public health
activities.
Based on the agreements of the blanket compensation,
all mass vaccinations before 27th January 1988 are
Figure 5 Prevalence of HBV carriers after repeated needle/syringe sharing.
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sharing. This was inevitable because it is difficult to
demonstrate which mass vaccinations were conducted
with needle/syringe sharing, and which were not.
However, this study suggests that needle/syringe
sharing was negligible in young cohorts born after 1980
because the prevalence of HBV carriers when they grewFigure 6 Modeling of HBV vertical and horizontal infection in childrenup was lower than their estimated prevalence at birth.
Although the official ban on needle/syringe sharing
was belated to 1988, disposable needle/syringe was
already common use by the middle of the 1970s. This
means that the assumption that there was needle/
syringe sharing in the 1980s cannot be justified by the
evidence..
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evidence that the prevalence of carrying HBV in adult-
hood more than doubled than the prevalence at birth. It is
possible that more than half of the HBV carriers of this co-
hort were infected through needle/syringe sharing. If the
probability of infection of HBV through needle/syringe
sharing is assumed to be 10%, it was demonstrated that
sharing a needle/syringe by five or more children four
times would have been enough to achieve their observed
prevalence in 1995. This finding will also serve as evidence
on how much needle/syringe sharing was practiced in
mass vaccination. Three witnesses testified in the land-
mark lawsuit filed in June 1989 in Hokkaido [18]. A public
health nurse who worked between 1951 and 1971 testified
that one needle/syringe had been shared by eight people
for TST and BCG inoculations (BCG was inoculated by
way of intradermal injection before 1967), and by ten
people for typhoid fever and paratyphoid vaccinations.
Another public health nurse who worked between 1962
and 1995 testified that 14–15 people shared a needle/
syringe for TST, 15–16 people for influenza vaccination,
and 7–8 people for diphtheria and pertussis vaccinations.
She also testified that disposable needle/syringes were in
common use by 1981. A medical doctor who worked for a
Sapporo city public health center testified that he had
injected 5–6 people without changing the needle/
syringe for TST, and added that all needle/syringes had
been replaced with disposable ones by 1975 in all public
health centers in Sapporo. The court determined that
sharing of a needle/syringe was common until 1969 or
1970, and upheld the plaintiff ’s claims.
Some municipalities departed from mass vaccination
to individual vaccination. The city of Kobe introduced
individual vaccinations as early as June 1969 by contrac-
ting out the practice to the local medical association
[19]. This evidence coincides with the finding of this
study that the gap between the prevalence of HBV car-
riers at birth and prevalence later in life was narrowed
after the cohorts born in the mid-1970s.
Practical implications
It is impossible to estimate exactly how many children
were infected through needle/syringe sharing and how
many through other routes. However, the mathematical
model presented in this article is able to provide a rough
estimate on the number of children infected through nee-
dle/syringe sharing in mass vaccination under estimated
prevalence and given conditions (see Figure 6).
In case of a cohort born between 1951 and 1955, the
model tells that the prevalence in 1995 (1.46%) would have
been achieved if more than five children shared a needle/
syringe four times given their estimated prevalence at
birth (0.65%) and the probability of infection (10%). If such
practice was plausible at that time, it would be reasonableto assume that most of the horizontal infection (1.46–
0.65% = 0.81%) was attributable to mass vaccination.
However, if the prevalence of this cohort in 1995 was
5%, the model tells that 5% prevalence would not have
been possible under the given conditions because it
requires either more than 15 children to share a needle/
syringe four times or more than ten children to share a
needle/syringe five times, which does not appear plausible.
Then one would assume that 3.54% (=5–1.46%) would
have been infected through other routes (infection
through needle/syringe sharing had a minor role com-
pared with other routes).
The model is also useful for public health profes-
sionals to assess the extent of accidental infections in
sporadic iatrogenic outbreaks still occurring in develo-
ping countries [20,21].
Conclusions
Japan achieved success in controlling infectious diseases
through mass vaccination programs in the postwar period.
On the other hand, Japan also had a bitter experience in
that many children were infected with HBV and became
carriers due to the mass vaccination program. More than
half of the HBV carriers born in the early 1950s might
have contracted the disease through mass vaccinations.
In the absence of firm evidence, the author presented
a mathematical model to estimate the extent of such
iatrogenic infection under certain conditions.
Japan’s experience needs to be shared with other coun-
tries as a caution in conducting mass vaccination pro-
grams under scarce needle/syringe supply.
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